X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BST02 is a tumor-infiltrating lymphocyte (TIL) therapy using a patient's own immune cells. It is being evaluated in phase 1 clinical trials for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
Lead Product(s): BST-02
Therapeutic Area: Oncology Product Name: BST-02
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
BST02 is a novel adoptive immune cell therapy that involves the expansion of tumor infiltrating lymphocytes derived from the patient's own cells. This therapy is specifically designed for the treatment of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
Lead Product(s): BST02
Therapeutic Area: Oncology Product Name: BST02
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
BRL03 developed by Biosyngen is an engineered T cell therapy, also known as a type of adoptive immune cell therapy for lung cancer, gastric cancer and other solid tumors.
Lead Product(s): BRL03
Therapeutic Area: Oncology Product Name: BRL03
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
